Invivyd (IVVD) Net Cash Flow (2021 - 2025)
Invivyd's (IVVD) quarterly Net Cash Flow came in at $141.7 million in Q4 2025, up 477.64% on a YoY basis from $24.5 million in Q4 2024, and up 183.09% quarter-over-quarter from $50.1 million in Q3 2025.
Analysis
Invivyd (IVVD) Net Cash Flow (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Net Cash Flow for 5 consecutive years, with $141.7 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow rose 477.64% year-over-year to $141.7 million; the trailing twelve-month figure through Dec 2025 stood at $157.3 million (up 219.83% YoY), and the FY2025 full-year result was $157.3 million, up 219.83% from the prior year.
- Net Cash Flow advanced to $141.7 million in Q4 2025 per IVVD's latest filing, from $50.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $301.3 million in Q2 2021 and bottomed at -$196.7 million in Q3 2022.
- Historically, Net Cash Flow has averaged $5.6 million across 5 years, with a median of -$10.6 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow tumbled 817.08% in 2024, then soared 477.64% in 2025.
- Over 5 years, Net Cash Flow stood at $64.0 million in 2021, then sank by 390.95% to -$186.1 million in 2022, then surged by 110.11% to $18.8 million in 2023, then tumbled by 299.42% to -$37.5 million in 2024, then jumped by 477.64% to $141.7 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $141.7 million, $50.1 million, and -$13.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 141.72 Mn |
| Sep 30, 2025 | 50.06 Mn |
| Jun 30, 2025 | -13.18 Mn |
| Mar 31, 2025 | -21.26 Mn |
| Dec 31, 2024 | -37.53 Mn |
| Sep 30, 2024 | -41.01 Mn |
| Jun 30, 2024 | -41.51 Mn |
| Mar 31, 2024 | -11.25 Mn |
| Dec 31, 2023 | 18.82 Mn |
| Sep 30, 2023 | 59.88 Mn |
| Jun 30, 2023 | -4.53 Mn |
| Mar 31, 2023 | 34.40 Mn |
| Dec 31, 2022 | -186.08 Mn |
| Sep 30, 2022 | -196.73 Mn |
| Jun 30, 2022 | -57.34 Mn |
| Mar 31, 2022 | -10.00 Mn |
| Dec 31, 2021 | 63.96 Mn |
| Sep 30, 2021 | 85.76 Mn |
| Jun 30, 2021 | 301.26 Mn |
| Mar 31, 2021 | -23.74 Mn |